Emil Lou

Emil Lou

University of Minnesota-Twin Cities

H-index: 37

North America-United States

About Emil Lou

Emil Lou, With an exceptional h-index of 37 and a recent h-index of 32 (since 2020), a distinguished researcher at University of Minnesota-Twin Cities, specializes in the field of cancer biology, gastrointestinal cancers, neuro-oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs)

Real-world analysis of insurance status and survival in patients with selected GI cancers

Comprehensive molecular and immunological characterization of early-onset esophagogastric cancer

AI enabled whole exome/transcriptome liquid biopsy addressing MCED, MRD, and therapy selection on a single platform

Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers

Tunneling nanotubes and tumor microtubes—Emerging data on their roles in intercellular communication and pathophysiology: Summary of an International FASEB Catalyst Conference …

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer

Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer

Emil Lou Information

University

Position

___

Citations(all)

5343

Citations(since 2020)

3887

Cited By

2855

hIndex(all)

37

hIndex(since 2020)

32

i10Index(all)

85

i10Index(since 2020)

69

Email

University Profile Page

Google Scholar

Emil Lou Skills & Research Interests

cancer biology

gastrointestinal cancers

neuro-oncology

Top articles of Emil Lou

The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs)

2023/6/1

Real-world analysis of insurance status and survival in patients with selected GI cancers

Cancer Research

2024/3/22

Brooke Patterson
Brooke Patterson

H-Index: 10

Emil Lou
Emil Lou

H-Index: 24

Comprehensive molecular and immunological characterization of early-onset esophagogastric cancer

EBioMedicine

2019/2/1

AI enabled whole exome/transcriptome liquid biopsy addressing MCED, MRD, and therapy selection on a single platform

Liver

2024/3/22

Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers

Molecular Therapy Oncology

2024/3/21

Tunneling nanotubes and tumor microtubes—Emerging data on their roles in intercellular communication and pathophysiology: Summary of an International FASEB Catalyst Conference …

2024/3/15

Emil Lou
Emil Lou

H-Index: 24

Frank Winkler
Frank Winkler

H-Index: 21

Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer

JAMA Network Open

2024/2/5

Emil Lou
Emil Lou

H-Index: 24

Axel Svedbom
Axel Svedbom

H-Index: 19

Molecular and immune landscape by cyclin dependent kinase (CDK) 4/6 expression and TP53 mutational status in mismatch repair deficient/microsatellite instability-high (dMMR/MSI …

2024/1/20

Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.

2024/1/20

Identification and characterization of immunogenic neoantigens in biliary cancer (BC) and pancreatic cancer (PC).

2024/1/20

High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or …

2024/1/20

Genomics and transcriptomics of pancreatic adenosquamous carcinoma.

2024/1/20

Sanjay Goel
Sanjay Goel

H-Index: 15

Emil Lou
Emil Lou

H-Index: 24

Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.

2024/1/20

APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive …

2024/1/20

Genomic analysis of oesophageal carcinoma (EC) to identify recurrent mutations in histone methyltransferases as a distinctive subset.

2024/1/20

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status

ESMO Gastrointestinal Oncology

2024/6/1

Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations

Journal of Experimental & Clinical Cancer Research

2022/4/2

See List of Professors in Emil Lou University(University of Minnesota-Twin Cities)